VivoSeq
Gastroenterology

Gastroparesis

59

Pipeline Programs↗

7

Active Trials↗

35

Companies Involved↗

Gastroparesis is a moderately active landscape with 59 programs across 35 companies. The most active players are EMD Serono, Pfizer, Theravance Biopharma. 11 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

6/100

Mech. Concentration

9/100

Completion Rate

64/100

Attrition Rate

30/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1T

Theravance Biopharma

2 programs

Phase 2C

CinDome Pharma, Inc.

1 program

Phase 2M

Motus Therapeutics, Inc.

1 program

Phase 2P

PTC Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical8

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Sapropterin Dihydrochloride

BioMarin Pharmaceutical

Immunotherapy

Bristol-Myers Squibb

Botulinum Toxin a

GSK

Phase 14

Somatropin

EMD Serono

Pioglitazone

Takeda

Growth Hormone

Pfizer

RQ-00000010

Virginia Commonwealth University

Phase 228

Buspirone

Bristol-Myers Squibb

Erythromycin

Azurity Pharmaceuticals

Rifaximin

Salix

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

RM-131

Motus Therapeutics, Inc.

Phase 38

Domperidone

Johnson & Johnson

Metoclopramide

Istituto Clinico Humanitas

Prucalopride

Takeda

Relamorelin

AbbVie

Tradipitant

Vanda Pharmaceuticals

Approved11

Oxytocin

Retrophin

Aprepitant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Granisetron

Conrado Roberto Hoffmann Filho

Methylnaltrexone

Salix

Tadalafil

Eli Lilly

Analysis

Modality Breakdown

98%

Small molecule

59 of 60 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody12%

Small molecule leads; the ring shows all 60 classified programs, each share of the total. Modality classified for 100% of 62 pipeline programs.

Analysis

Trial Status

73

clinical trials

Completed39 · 53%
Terminated19 · 26%
Recruiting6 · 8%
Withdrawn3 · 4%
Unknown status2 · 3%
Available2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

73 trials

Growth Hormone for the Treatment of Gastroparesis
Recruiting·MMayo Clinic·Phase 1·NCT06803589·10 enrolled
Different Doses of Naronapride Vs. Placebo in Gastroparesis
Recruiting·—·Phase 2·NCT05621811·320 enrolled
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Recruiting·VVanda Pharmaceuticals·Phase 3·NCT06836557·100 enrolled
Compassionate Use of Domperidone for Refractory Gastroparesis
Recruiting·—·N/A·NCT04699591·20 enrolled
Effect of Itopride on Semaglutide Gastroparesis
Recruiting·—·Phase 4·NCT07254715·60 enrolled
Gastroparesis Outcome Longitudinal Database Enrolled Numerically
Recruiting·UUniversity of Louisville·N/A·NCT03876288·3,000 enrolled
A Randomized, Sham-controlled Trial: Endoscopic Myotomy of the Pylorus To Improve Emptying and Symptoms (EMPTIES)
Active, not recruiting·—·Preclinical·NCT05039424·100 enrolled
Buspirone for Early Satiety and Symptoms of Gastroparesis
Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 2·NCT03587142·96 enrolled
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
Completed·CCinDome Pharma, Inc.·Phase 2·NCT05832151·382 enrolled
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
Completed·MMayo Clinic·Phase 2·NCT03941288·92 enrolled
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
Completed·TTranzyme, Inc.·Phase 2·NCT01452815·201 enrolled
A Study of CNSA-001 in Women With Diabetic Gastroparesis
Completed·PPTC Therapeutics·Phase 2·NCT03712124·21 enrolled
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
Completed·PProcessa Pharmaceuticals·Phase 2·NCT05270460·25 enrolled
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis
Completed·TTranzyme, Inc.·Phase 2·NCT00612014·78 enrolled
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis
Completed·EEvoke Pharma·Phase 2·NCT00845858·287 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)